: Evaluating whether the viral vector or therapeutic gene could unintentionally be passed on to future generations.
: This guideline is a cornerstone for developers of Advanced Therapy Medicinal Products (ATMPs) in the European Union.
For more detailed technical specifications, you can access the full Guideline on Non-Clinical Studies for GTMPs via the official . 125459
The guideline, officially titled , provides a framework for non-clinical studies required before a gene therapy can be used in human clinical trials. Guide to EMA Guideline 125459
This document outlines the essential safety and efficacy data that developers must generate during the "non-clinical" (animal or lab) phase to justify moving into human subjects. : Evaluating whether the viral vector or therapeutic
The number most commonly refers to a specific scientific guideline established by the European Medicines Agency (EMA) regarding the development of Gene Therapy Medicinal Products (GTMPs) .
: Characterizing potential immune responses to the viral vector or the new protein produced by the therapy. The guideline, officially titled , provides a framework
: Determining where the therapeutic gene goes in the body and how long it persists in both target and non-target cells.